Overview
International law firm McDermott Will & Emery represented Vanda Pharmaceuticals Inc. (Vanda), a leading global biopharmaceutical company, in its acquisition of US and Canadian rights to PONVORY®, a treatment for adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
The McDermott deal team was led by Kristian Werling with support from Paul Hughes, Nate Wolfe, Tom Conaghan, Caroline Ngo, Daniel McGuire, Dave Santangelo, Matt Celano, Alex Ruiz, Yuxin Jin, Dan Marino, Margaret Sampson, Anisa Mohanty, Scott Weinstein and Dana McSherry.
Read Vanda’s announcement here.
